<DOC>
	<DOCNO>NCT00039026</DOCNO>
	<brief_summary>This multicenter , randomize , blind , placebo-controlled study ass effect glucose control AC2993 compare placebo patient type 2 diabetes . Patients randomize one two AC2993 treatment arm placebo treatment continue require exist diabetes medication ( sulfonylurea ) throughout study .</brief_summary>
	<brief_title>Evaluation Effect Glucose Control AC2993 Patients With Type 2 Diabetes Mellitus Treated With Sulfonylurea</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>Subjects Type 2 diabetes mellitus Treated sulfonylurea define dos least 3 month prior screen BMI= 2745 kg/m2 HbA1c value 7.5 % 11 % Treated oral antidiabetic medication sulfonylurea within 3 month screen Patients treat previously AC2993 Patients presently treat insulin</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Type 2 Diabetes Mellitis</keyword>
</DOC>